Notably we observed a decreased dependency on BCR signaling for metabolic activity in CLL harboring deletions of chromosome 17p (which includes the TP53 gene), which is known marker of worse prognosis in CLL [73]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.